Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
NCT06483139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 549
Last updated 2026-07-09
Summary
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
Conditions
- Multiple Myeloma
- Light Chain Nephropathy
- Acute Kidney Injury
Interventions
- PROCEDURE
-
Plasma exchange
Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
- DRUG
-
Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Sponsors & Collaborators
-
Janssen, LP
collaborator INDUSTRY -
Baystate Health
collaborator OTHER -
Boston Medical Center
collaborator OTHER - collaborator OTHER
-
Massachusetts General Hospital
collaborator OTHER - collaborator OTHER
-
M.D. Anderson Cancer Center
collaborator OTHER -
Medical University of South Carolina
collaborator OTHER -
H. Lee Moffitt Cancer Center and Research Institute
collaborator OTHER -
Icahn School of Medicine at Mount Sinai
collaborator OTHER -
Northwell Health
collaborator OTHER -
Ochsner Health System
collaborator OTHER -
Ohio State University
collaborator OTHER - collaborator OTHER
-
Texas Medical Center
collaborator UNKNOWN -
Thomas Jefferson University
collaborator OTHER -
University of Alabama at Birmingham
collaborator OTHER -
University of California, Los Angeles
collaborator OTHER - collaborator OTHER
-
University of Colorado Health
collaborator OTHER - collaborator OTHER
-
University of New Mexico
collaborator OTHER - collaborator OTHER
- collaborator OTHER
-
University of Virginia
collaborator OTHER - collaborator OTHER
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shruti Gupta, MD · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-06-01
- Primary Completion
- 2026-06-01
- Completion
- 2026-06-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy
NCT02358980 ·Status: COMPLETED
-
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT
NCT04286477 ·Status: UNKNOWN
-
The Effect of On-line Hemodiafiltratrion on Nutritional Status and Body Composition
NCT03190629 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure
NCT00280072 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)
NCT00369096 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease
NCT02021019 ·Status: COMPLETED ·Phase: NA
-
Interventions Made to Preserve Cognitive Function
NCT03616535 ·Status: TERMINATED ·Phase: NA
-
Impact of Clotting on Dialyzer Efficiency
NCT04746391 ·Status: COMPLETED ·Phase: NA
-
Study of 2 Modalities of Dialysis and Nutrition on the Nutritional Status of Malnourished Chronic Renal Disease Patients
NCT04445558 ·Status: COMPLETED ·Phase: NA
-
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
NCT04002440 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction
NCT06129617 ·Status: RECRUITING ·Phase: NA
-
Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis
NCT01062984 ·Status: COMPLETED ·Phase: NA
-
An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
NCT04198012 ·Status: COMPLETED ·Phase: NA
-
Mechanisms and Treatment of Intradialytic Hypertension - Sodium
NCT01371890 ·Status: COMPLETED
-
Renal Denervation in Chronic Kidney Disease - RDN-CKD Study
NCT04264403 ·Status: COMPLETED ·Phase: NA
-
Reduction of Microemboli of Air Using a New Developed Air Trap (EmbolessTM) During Haemodialysis
NCT06168539 ·Status: COMPLETED ·Phase: NA
-
Renal Denervation in Patients With Chronic Heart Failure
NCT02085668 ·Status: WITHDRAWN ·Phase: NA
-
The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients
NCT04094038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
L-Cysteine in Peritoneal Dialysis
NCT02050139 ·Status: COMPLETED ·Phase: PHASE2
-
Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis
NCT01892839 ·Status: UNKNOWN ·Phase: NA
-
Cell-based Therapy for the Treatment of Kidney Disease
NCT04187625 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Transcapillary Plasma Refill in Advanced Chronic Kidney Disease
NCT03348488 ·Status: COMPLETED ·Phase: NA
-
Biological Determinants of Peritoneal Dialysis
NCT02694068 ·Status: COMPLETED
-
Evaluation of Contact Phase Activation During Hemodialysis
NCT03090984 ·Status: COMPLETED ·Phase: NA
-
Hemodialysis-based Interventions to Preserve Cognitive Function
NCT02697942 ·Status: TERMINATED ·Phase: NA
Entities
- Dana-Farber Cancer Institute
- Icahn School of Medicine at Mount Sinai
- Massachusetts General Hospital
- Mayo Clinic
- Medical University of South Carolina
- Stanford University
- University of Alabama at Birmingham
- University of California, Los Angeles
- University of Chicago
- University of Minnesota
- University of Pennsylvania
- University of Pittsburgh
- University of Washington